Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 393-398

  Jutten, Barry ^a   Dubois, Ludwig ^a   Li, Younan ^a   Aerts, Hugo ^a   Wouters, Bradly G ^a,b,c   Lambin, Philippe ^a   Theys, Jan ^a   Lammering, Guido ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Cetuximab; EGFRvIII; Glioma; Radiotherapy; Targeted therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA MODIFICATION; DRUG RECEPTOR BINDING; GENE DELETION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RECEPTOR UPREGULATION;

ANTIBODIES, MONOCLONAL; BINDING SITES; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICROSCOPY, CONFOCAL; PROBABILITY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 70249096306     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.021     Document Type: Article

References (32)

1. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
2. Harari P.M., Allen G.W., and Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25 (2007) 4057-4065
3. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
4. Jhawer M., Goel S., Wilson A.J., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (2008) 1953-1961
5. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
6. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
7. Krause M., Prager J., Zhou X., et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol 83 (2007) 316-325
8. Lammering G. Molecular predictor and promising target: will EGFR now become a star in radiotherapy?. Radiother Oncol 74 (2005) 89-91
9. Lammering G., Hewit T.H., Holmes M., et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10 (2004) 6732-6743
10. Ge H., Gong X., and Tang C.K. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98 (2002) 357-361
11. Okamoto I., Kenyon L.C., Emlet D.R., et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94 (2003) 50-56
12. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006) 5064-5073
13. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
14. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
15. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (2002) 1S-13S
16. Yoshida T., Okamoto I., Okabe T., et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 122 (2008) 1530-1538
17. Aerts H.J., Dubois L., Hackeng T.M., et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 83 (2007) 326-332
18. Weppler S.A., Li Y., Dubois L., et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 83 (2007) 333-339
19. Toulany M., Baumann M., and Rodemann H.P. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 5 (2007) 863-872
20. Toulany M., Kehlbach R., Florczak U., et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7 (2008) 1772-1781
21. Lammering G., Hewit T.H., Valerie K., et al. EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22 (2003) 5545-5553
22. Gupta A.K., Cerniglia G.J., Mick R., McKenna W.G., and Muschel R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 65 (2005) 8256-8265
23. Aerts H.J., Dubois L., Perk L., et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50 (2009) 123-131
24. Pan X., Wu G., Yang W., Barth R.F., Tjarks W., and Lee R.J. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 18 (2007) 101-108
25. Wu G., Barth R.F., Yang W., Kawabata S., Zhang L., and Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 5 (2006) 52-59
26. Morgillo F., Woo J.K., Kim E.S., Hong W.K., and Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66 (2006) 10100-10111
27. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., Amorino G., and Lin P.S. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22 (2003) 5855-5865
28. Mandic R., Rodgarkia-Dara C.J., Zhu L., et al. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580 (2006) 4793-4800
29. Ning Y., Zeineldin R., Liu Y., Rosenberg M., Stack M.S., and Hudson L.G. Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res 65 (2005) 9280-9286
30. Ning Y., Buranda T., and Hudson L.G. Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway. J Biol Chem 282 (2007) 6380-6387
31. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 76 (2005) 157-161
32. Wikstrand C.J., McLendon R.E., Friedman A.H., and Bigner D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57 (1997) 4130-4140